Fortress Biotech, Inc. (NASDAQ: FBIO)

Fortress Biotech, Inc., a company that operates in the biotechnology industry, is dedicated to enhancing long-term value for its shareholders through product revenue, equity holdings, and dividend and royalty revenue streams. The company's operations span various stages of development, with a diverse portfolio of products and product candidates.

Fortress Biotech's main business activities involve the acquisition and advancement of assets. The company generates revenue through the sale of branded dermatology products, such as Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm, and Targadox, as well as authorized generic products like sulconazole nitrate cream and solution. Additionally, Fortress earns revenue through licensing agreements and royalties from its partners.

One of the company's primary products is Qbrexza, a medicated cloth towelette for treating primary axillary hyperhidrosis. Qbrexza is marketed by Journey Medical Corporation, a subsidiary of Fortress, and has received approval from the U.S. Food and Drug Administration (FDA). Furthermore, Fortress Biotech has a number of product candidates in various stages of development, including cosibelimab, a PD-L1 antibody being developed by Checkpoint Therapeutics for the treatment of solid tumors; DFD-29, a modified release oral minocycline being developed by Journey for the treatment of rosacea; CUTX-101, a copper histidinate injection being developed by Cyprium Therapeutics for the treatment of Menkes disease; and IV tramadol, an intravenous formulation of tramadol being developed by Avenue Therapeutics for the treatment of post-operative acute pain.

In terms of its competitive advantage, Fortress Biotech boasts a strong portfolio of products and product candidates, as well as a number of partnerships and collaborations with other companies. These partnerships include City of Hope National Medical Center, Fred Hutchinson Cancer Center, St. Jude Children's Research Hospital, Dana-Farber Cancer Institute, and Mayo Foundation for Medical Education and Research. Additionally, the company has collaborations with pharmaceutical companies such as AstraZeneca plc and Dr. Reddy's Laboratories, Ltd.

Fortress Biotech's customers include a number of pharmaceutical companies and research institutions, such as City of Hope National Medical Center, Fred Hutchinson Cancer Center, St. Jude Children's Research Hospital, Dana-Farber Cancer Institute, and Mayo Foundation for Medical Education and Research. The company's position within the industry is strong, with a diverse portfolio of products and product candidates in various stages of development. Fortress's partnerships and collaborations with other companies also give it a competitive advantage, as well as its focus on acquiring and advancing assets.